In a cost-utility analysis in the Philippines, adjuvant trastuzumab therapy (all cycles) for HER2/neu positive early breast cancer was not cost-effective (in addition to chemotherapy) and remains unaffordable at its 2017 government-negotiated price of PHP 619,667 (USD 11,161) [22]. The gene discussed is ERBB2; the disease is breast carcinoma.